Treatment and disease-specific survival differences among veterans with Merkel cell carcinoma
- PMID: 40490100
- DOI: 10.1016/j.jaad.2025.06.007
Treatment and disease-specific survival differences among veterans with Merkel cell carcinoma
Keywords: MCC; Merkel cell carcinoma; SEER; VA; Veterans Affairs; cutaneous; dermatology; oncology; surveillance, epidemiolgy, and end results program; veteran.
Conflict of interest statement
Conflicts of interest Mr Kim is a paid consultant for Verve Therapeutics and SeQure Dx, unrelated to this research. Mr Hippe has received research funding from GE Healthcare,outside of the submitted work. Dr Hartman is a scientific officer for Evereden, unrelated to this research. Dr Hartman is a consultant and has received honoraria from Oasis Pharmaceuticals, Almirall, Med Learning Group, and MJH Life Sciences, outside the scope of the submitted work. The interests of Mr Kim and Dr Hartman have been reviewed and are managed by the Veterans Health Administration and Mass General Brigham in accordance with their conflict-of-interest policies. Drs Huhmann, Wheless, Pavlis, Brophy, Do, Nghiem, Fillmore, and Author Hwang have no conflicts of interest to disclose.
Grants and funding
LinkOut - more resources
Full Text Sources